{"page_content": "ESG R eport 2022\nGlobal Access \nPYRUKYND\u00ae is currently only approved and available in the U.S., \nand is under regulatory review in the EU with a decision expected by \nthe end of 2022.\nAgios is reviewing options with both partners and distributors to \ndetermine the best path forward for access in additional global \nmarkets.\nList of products on the WHO List of Prequalified Medicinal \nProducts as part of its Prequalification of Medicines  \nProgramme (PQP)  \nSASB: HC-BP-240A.2\nGiven the focus on genetically defined disease medications,  \nAgios\u2019 products do not qualify for the WHO List of Prequalified \nMedicinal Products.\nNumber of settlements of Abbreviated New Drug Application \n(ANDA) litigation that involved payments and/or provisions to \ndelay bringing an authorized generic product to market for a \ndefined time period  \nSASB: HC-BP-240B.1\nNoneAccess to Medicines  and Affordable Pricing Strategy\nOur Pledge\nWe have pledged to price our medicines in a way that reflects the \nbenefits to patients, caregivers, the healthcare system and society and \nallows us to help as many people as possible today while investing in \ninnovation to help even more people tomorrow.\nAs part of our commitment, we are not taking any price increases  \non PYRUKYND\u00ae for the next five years.\nJonathan, living with PK deficiency,  \nand his mom Alejandra12", "metadata": {"source": "NASDAQ_AGIO_2021.pdf", "page": 11, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}